218 related articles for article (PubMed ID: 14752066)
1. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.
Marchetti M; Barosi G; Balestri F; Viarengo G; Gentili S; Barulli S; Demory JL; Ilariucci F; Volpe A; Bordessoule D; Grossi A; Le Bousse-Kerdiles MC; Caenazzo A; Pecci A; Falcone A; Broccia G; Bendotti C; Bauduer F; Buccisano F; Dupriez B
J Clin Oncol; 2004 Feb; 22(3):424-31. PubMed ID: 14752066
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Thomas DA; Giles FJ; Albitar M; Cortes JE; Verstovsek S; Faderl S; O'Brien SM; Garcia-Manero G; Keating MJ; Pierce S; Zeldis J; Kantarjian HM
Cancer; 2006 May; 106(9):1974-84. PubMed ID: 16583431
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies.
Barosi G; Elliott M; Canepa L; Ballerini F; Piccaluga PP; Visani G; Marchetti M; Pozzato G; Zorat F; Tefferi A
Leuk Lymphoma; 2002 Dec; 43(12):2301-7. PubMed ID: 12613516
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study.
Abgrall JF; Guibaud I; Bastie JN; Flesch M; Rossi JF; Lacotte-Thierry L; Boyer F; Casassus P; Slama B; Berthou C; Rodon P; Leporrier M; Villemagne B; Himberlin C; Ghomari K; Larosa F; Rollot F; Dugay J; Allard C; Maigre M; Isnard F; Zerbib R; Cauvin JM;
Haematologica; 2006 Aug; 91(8):1027-32. PubMed ID: 16885042
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study.
Piccaluga PP; Visani G; Pileri SA; Ascani S; Grafone T; Isidori A; Malagola M; Finelli C; Martinelli G; Ricci P; Baccarani M; Tura S
Leukemia; 2002 Sep; 16(9):1609-14. PubMed ID: 12200671
[TBL] [Abstract][Full Text] [Related]
6. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic.
Mesa RA; Nagorney DS; Schwager S; Allred J; Tefferi A
Cancer; 2006 Jul; 107(2):361-70. PubMed ID: 16770787
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide for the treatment of idiopathic myelofibrosis.
Strupp C; Germing U; Scherer A; Kündgen A; Mödder U; Gattermann N; Haas R
Eur J Haematol; 2004 Jan; 72(1):52-7. PubMed ID: 14962263
[TBL] [Abstract][Full Text] [Related]
8. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.
Mesa RA; Elliott MA; Schroeder G; Tefferi A
Mayo Clin Proc; 2004 Jul; 79(7):883-9. PubMed ID: 15244384
[TBL] [Abstract][Full Text] [Related]
9. A phase-2 trial of low-dose pomalidomide in myelofibrosis.
Begna KH; Mesa RA; Pardanani A; Hogan WJ; Litzow MR; McClure RF; Tefferi A
Leukemia; 2011 Feb; 25(2):301-4. PubMed ID: 21052089
[TBL] [Abstract][Full Text] [Related]
10. [Low-dose thalidomide in refractory and relapsing multiple myeloma].
Radocha J; Maisnar V
Vnitr Lek; 2007 Feb; 53(2):129-34. PubMed ID: 17419173
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens.
Cuadrado MJ; Karim Y; Sanna G; Smith E; Khamashta MA; Hughes GR
Am J Med; 2005 Mar; 118(3):246-50. PubMed ID: 15745722
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
Mesa RA; Steensma DP; Pardanani A; Li CY; Elliott M; Kaufmann SH; Wiseman G; Gray LA; Schroeder G; Reeder T; Zeldis JB; Tefferi A
Blood; 2003 Apr; 101(7):2534-41. PubMed ID: 12517815
[TBL] [Abstract][Full Text] [Related]
13. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
Duan M; Zhou D
Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
[No Abstract] [Full Text] [Related]
14. Low-dose thalidomide in myelofibrosis.
Weinkove R; Reilly JT; McMullin MF; Curtin NJ; Radia D; Harrison CN
Haematologica; 2008 Jul; 93(7):1100-1. PubMed ID: 18508796
[No Abstract] [Full Text] [Related]
15. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.
Radin AI; Kim HT; Grant BW; Bennett JM; Kirkwood JM; Stewart JA; Hahn RG; Dutcher JP; Wiernik PH; Oken MM;
Cancer; 2003 Jul; 98(1):100-9. PubMed ID: 12833462
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.
Barosi G; Grossi A; Comotti B; Musto P; Gamba G; Marchetti M
Br J Haematol; 2001 Jul; 114(1):78-83. PubMed ID: 11472348
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial using thalidomide for Langerhans cell histiocytosis.
McClain KL; Kozinetz CA
Pediatr Blood Cancer; 2007 Jan; 48(1):44-9. PubMed ID: 16333818
[TBL] [Abstract][Full Text] [Related]
18. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003.
Mesa RA
Curr Hematol Rep; 2003 May; 2(3):264-70. PubMed ID: 12901349
[TBL] [Abstract][Full Text] [Related]
19. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia.
Faoro LN; Tefferi A; Mesa RA
Eur J Haematol; 2005 Feb; 74(2):117-20. PubMed ID: 15654901
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy.
Maurer T; Poncelet A; Berger T
Arch Dermatol; 2004 Jul; 140(7):845-9. PubMed ID: 15262695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
